NEW DELHI: Dr Reddy’s has entered into a licence agreement with Pharmazz, a US based biopharmaceutical company, to commercialise a first-in-class innovative drug Centhaquine in India.
Developed by Pharmazz, Centhaquine is a resuscitative agent, presently indicated for the treatment of hypovolemic shock, by the Drugs Controller General of India (DCGI), says a company statement.
As per the agreement, Dr Reddy’s has received exclusive rights to market and distribute Centhaquine in India. Pharmazz will be entitled to upfront payments and royalties.
India is the first global territory in which Centhaquine (Lyfaquin) is being launched immediately.
MV Ramana, CEO branded markets (India and emerging markets), Dr Reddy’s, said, “The clinical studies for Lyfaquin have demonstrated significantly better and promising outcomes, making it as a potential add-on drug in the management of hypovolemic shock and enhancing the current standard of care for its treatment in India.”
Centhaquine is a frontline therapy used along with the standard of care and is well-positioned to a critical unmet need as a pharmacologically active resuscitative agent. A decrease in the volume of blood circulation from blood or fluid loss due to trauma, gastrointestinal bleeding, major surgery, postpartum hemorrhage, diarrhea, or vomiting can cause hypovolemic shock, it adds.
Developed by Pharmazz, Centhaquine is a resuscitative agent, presently indicated for the treatment of hypovolemic shock, by the Drugs Controller General of India (DCGI), says a company statement.
As per the agreement, Dr Reddy’s has received exclusive rights to market and distribute Centhaquine in India. Pharmazz will be entitled to upfront payments and royalties.
India is the first global territory in which Centhaquine (Lyfaquin) is being launched immediately.
MV Ramana, CEO branded markets (India and emerging markets), Dr Reddy’s, said, “The clinical studies for Lyfaquin have demonstrated significantly better and promising outcomes, making it as a potential add-on drug in the management of hypovolemic shock and enhancing the current standard of care for its treatment in India.”
Centhaquine is a frontline therapy used along with the standard of care and is well-positioned to a critical unmet need as a pharmacologically active resuscitative agent. A decrease in the volume of blood circulation from blood or fluid loss due to trauma, gastrointestinal bleeding, major surgery, postpartum hemorrhage, diarrhea, or vomiting can cause hypovolemic shock, it adds.